Promising approaches in acute leukemia

Jorge Cortes, Hagop M. Kantarjian

Research output: Contribution to journalReview article

Abstract

In the last few decades, there has been a significant improvement in the prognosis of patients with acute leukemias. Still, the majority of patients succumb to these diseases. In recent years there has been a great surge in the understanding of the molecular mechanisms of disease which have provided us with new targets for anti-leukemia therapy. These range from chemotherapeutic agents with novel mechanisms of action, such as topoisomerase I inhibitors or demethylating agents, to reversal of drug-resistance mechanisms, to monoclonal antibodies directed against specific antigens, and targeted therapy that inhibit the function of molecules such as tyrosine kinases or Ras. The research on many of these agents is still in the early phases, but these new approaches offer the promise of finding a cure for the majority of patients with leukemia in the near future. Here we describe some of the promising approaches that are currently being investigated in the treatment of acute leukemias.

Original languageEnglish (US)
Pages (from-to)57-82
Number of pages26
JournalInvestigational New Drugs
Volume18
Issue number1
DOIs
StatePublished - Apr 11 2000
Externally publishedYes

Fingerprint

Leukemia
Topoisomerase I Inhibitors
Drug Resistance
Protein-Tyrosine Kinases
Therapeutics
Monoclonal Antibodies
Antigens
Research

Keywords

  • Acute leukemia
  • Immunomodulation
  • Monoclonal antibodies
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Promising approaches in acute leukemia. / Cortes, Jorge; Kantarjian, Hagop M.

In: Investigational New Drugs, Vol. 18, No. 1, 11.04.2000, p. 57-82.

Research output: Contribution to journalReview article

Cortes, Jorge ; Kantarjian, Hagop M. / Promising approaches in acute leukemia. In: Investigational New Drugs. 2000 ; Vol. 18, No. 1. pp. 57-82.
@article{5cf39ad45fc24917943741f62f0b0c02,
title = "Promising approaches in acute leukemia",
abstract = "In the last few decades, there has been a significant improvement in the prognosis of patients with acute leukemias. Still, the majority of patients succumb to these diseases. In recent years there has been a great surge in the understanding of the molecular mechanisms of disease which have provided us with new targets for anti-leukemia therapy. These range from chemotherapeutic agents with novel mechanisms of action, such as topoisomerase I inhibitors or demethylating agents, to reversal of drug-resistance mechanisms, to monoclonal antibodies directed against specific antigens, and targeted therapy that inhibit the function of molecules such as tyrosine kinases or Ras. The research on many of these agents is still in the early phases, but these new approaches offer the promise of finding a cure for the majority of patients with leukemia in the near future. Here we describe some of the promising approaches that are currently being investigated in the treatment of acute leukemias.",
keywords = "Acute leukemia, Immunomodulation, Monoclonal antibodies, Therapy",
author = "Jorge Cortes and Kantarjian, {Hagop M.}",
year = "2000",
month = "4",
day = "11",
doi = "10.1023/A:1006392116024",
language = "English (US)",
volume = "18",
pages = "57--82",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Promising approaches in acute leukemia

AU - Cortes, Jorge

AU - Kantarjian, Hagop M.

PY - 2000/4/11

Y1 - 2000/4/11

N2 - In the last few decades, there has been a significant improvement in the prognosis of patients with acute leukemias. Still, the majority of patients succumb to these diseases. In recent years there has been a great surge in the understanding of the molecular mechanisms of disease which have provided us with new targets for anti-leukemia therapy. These range from chemotherapeutic agents with novel mechanisms of action, such as topoisomerase I inhibitors or demethylating agents, to reversal of drug-resistance mechanisms, to monoclonal antibodies directed against specific antigens, and targeted therapy that inhibit the function of molecules such as tyrosine kinases or Ras. The research on many of these agents is still in the early phases, but these new approaches offer the promise of finding a cure for the majority of patients with leukemia in the near future. Here we describe some of the promising approaches that are currently being investigated in the treatment of acute leukemias.

AB - In the last few decades, there has been a significant improvement in the prognosis of patients with acute leukemias. Still, the majority of patients succumb to these diseases. In recent years there has been a great surge in the understanding of the molecular mechanisms of disease which have provided us with new targets for anti-leukemia therapy. These range from chemotherapeutic agents with novel mechanisms of action, such as topoisomerase I inhibitors or demethylating agents, to reversal of drug-resistance mechanisms, to monoclonal antibodies directed against specific antigens, and targeted therapy that inhibit the function of molecules such as tyrosine kinases or Ras. The research on many of these agents is still in the early phases, but these new approaches offer the promise of finding a cure for the majority of patients with leukemia in the near future. Here we describe some of the promising approaches that are currently being investigated in the treatment of acute leukemias.

KW - Acute leukemia

KW - Immunomodulation

KW - Monoclonal antibodies

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0034028747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034028747&partnerID=8YFLogxK

U2 - 10.1023/A:1006392116024

DO - 10.1023/A:1006392116024

M3 - Review article

C2 - 10830141

AN - SCOPUS:0034028747

VL - 18

SP - 57

EP - 82

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -